News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Melphalan-prednisone-bortezomib improves HRQoL in intermediate-fit and frail NDMM patients
22 Jul 2024
byNatalia Reoutova
Treatment with melphalan-prednisone-bortezomib (MPV) improves health-related quality of life (HRQoL) in both intermediate-fit and frail newly diagnosed multiple myeloma (NDMM) patients, according to the results of the prospective phase II HOVON123 trial.
22 Jul 2024







